Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024 An asset write down of NZ$8.5 million (A$7.86m) saw New Zealand-based Rua Bioscience post a loss […]
Company news: Rua Bioscience; Avecho; Bioxyne/BLS; iX Biopharma; Ecofibre; Zelira by Steve Jones and Martin Lane August 28, 2024January 13, 2025
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024
Cann Group vows to ‘vigorously’ defend Rua claims as contract dispute goes legal by Steve Jones February 16, 2024November 25, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: MedReleaf; Vitura Health; MGC Pharma; Rua Bioscience by Martin Lane April 13, 2023April 30, 2024
Rua Bioscience vows to continue product supply despite taking axe to local manufacturing by Steve Jones March 27, 2023April 30, 2024
